TER 286: Clinical Trials

3 trials of TER 286, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1

Follow TER 286: new trials by email Literature Review of TER 286 trials Research Report on TER 286

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Telcyta, Liposomal Doxorubicin - Ovarian Neoplasms
Phase 3TerminatedTelik2442006-05-012013-11-27
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection - Ovarian Neoplasms
Phase 3CompletedTelik2442004-12-012012-05-31
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa) - Non Small Cell Lung Carcinoma
Phase 3CompletedTelik5202008-01-15

Conditions studied

Ovarian Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)

Sponsors

Telik (3)

Countries

United States (3)  ·  Brazil (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Chile (1)  ·  Germany (1)  ·  Italy (1)

Top investigators

Gail L. Brown, MD, MBA (1)

Results publications

PMID 37407274, PMID 20973267